Interleukin 6: from bench to bedside (original) (raw)
Yoshizaki K et al. (1984) Isolation and characterization of B cell differentiation factor (BCDF) secreted from a human B lymphoblastoid cell line. J Immunol132: 2948–2954 CASPubMed Google Scholar
Hirano T et al. (1986) Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature324: 73–76 ArticleCAS Google Scholar
Wolvekamp MC and Marquet RL (1990) Interleukin-6: historical background, genetics and biological significance. Immunol Lett24: 1–9 ArticleCAS Google Scholar
Nemeth E et al. (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest113: 1271–1276 ArticleCAS Google Scholar
Weber J et al. (1993) Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol11: 499–506 ArticleCAS Google Scholar
Nakahara H et al. (2003) Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum48: 1521–1529 ArticleCAS Google Scholar
Tamura T et al. (1993) Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6. Proc Natl Acad Sci USA90: 11924–11928 ArticleCAS Google Scholar
Kawano M et al. (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature332: 83–85 ArticleCAS Google Scholar
Miki S et al. (1989) Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett250: 607–610 ArticleCAS Google Scholar
Horii Y et al. (1989) Involvement of interleukin-6 in mesangial proliferation of glomerulonephritis. J Immunol143: 3949–3955 CASPubMed Google Scholar
Klein B et al. (1989) Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood73: 517–526 CASPubMed Google Scholar
Suematsu S et al. (1989) IgG1 plasmacytosis in interleukin-6 transgenic mice. Proc Natl Acad Sci USA86: 7547–7551 ArticleCAS Google Scholar
Suematsu S et al. (1992) Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc Natl Acad Sci USA89: 232–235 ArticleCAS Google Scholar
Olsen NJ and Stein CM (2004) New drugs for rheumatoid arthritis. N Engl J Med350: 2167–2179 ArticleCAS Google Scholar
Keane J et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med345: 1098–1104 ArticleCAS Google Scholar
Sack U et al. (1993) Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol Int13: 45–51 ArticleCAS Google Scholar
Madhok R et al. (1993) Serum interleukin 6 levels in rheumatoid arthritis: correlation with clinical and laboratory indices of disease activity. Ann Rheum Dis52: 232–234 ArticleCAS Google Scholar
Pawlik A et al. (2005) IL-6 promoter polymorphism in patients with rheumatoid arthritis. Scand J Rheumatol34: 109–113 ArticleCAS Google Scholar
Atsumi T et al. (2002) A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med196: 979–990 ArticleCAS Google Scholar
Alonzi T et al. (1998) Interleukin-6 is required for the development of collagen-induced arthritis. J Exp Med187: 461–468 ArticleCAS Google Scholar
Sasai M et al. (1999) Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum42: 1635–1643 ArticleCAS Google Scholar
Hata H et al. (2004) Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest114: 582–588 ArticleCAS Google Scholar
Takagi N et al. (1998) Blockage of Interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum41: 2117–2121 ArticleCAS Google Scholar
Mihara M et al. (2001) Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys. Clin Immunol98: 319–326 ArticleCAS Google Scholar
Montero-Julian FA et al. (1995) Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies. Blood85: 917–924 CASPubMed Google Scholar
Sato K et al. (1993) Reshaping a human antibody to inhibit the interleukin-6-dependent tumor cell growth. Cancer Res53: 851–856 CASPubMed Google Scholar
Nishimoto N et al. (2003) Toxicity, pharmacokinetics, and dose finding study of repetitive treatment with humanized anti-interleukin 6 receptor antibody, MRA, in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol30: 1426–1435 CASPubMed Google Scholar
Choy EH et al. (2002) Therapeutic benefit after blocking interleukin-6 activity in rheumatoid arthritis with an anti-interleukin-6 receptor monoclonal antibody. Arthritis Rheum46: 3143–3150 ArticleCAS Google Scholar
Nishimoto N et al. (2004) Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum50: 1761–1769 ArticleCAS Google Scholar
Maini RN et al. (2003) Efficacy of IL-6 receptor antagonist MRA in rheumatoid arthritis patients with an incomplete response to methotrexate (CHARISMA) [abstract #1704]. Arthritis Rheum48 (Suppl): S652 Google Scholar
Felson DT et al. (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum38: 727–735 ArticleCAS Google Scholar
Gillmor JD et al. (2001) Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet358: 24–29 Article Google Scholar
Sasaki A et al. (2000) CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem275: 29338–29347 ArticleCAS Google Scholar
Nishimoto N et al. (2005) Blocking interleukin-6 (IL-6) by tocilizumab (a humanized anti-interleukin-6 receptor monoclonal antibody) monotherapy reduces joint damage in active rheumatoid arthritis (RA): evidence from a X-ray reader-blinded randomised controlled trial [abstract #L27]. Arthritis Rheum52 (Suppl)
Petty RE et al. (2004) International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol31: 390–392 PubMed Google Scholar
Martini A et al. (1994) Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis. Lancet344: 1052–1054 ArticleCAS Google Scholar
Cazzola M et al. (1996) Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood87: 4824–4830 CASPubMed Google Scholar
Quartier P et al. (2003) Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum48: 1093–1101 ArticleCAS Google Scholar
Ramanan AV and Schneider R (2003) Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol30: 401–403 PubMed Google Scholar
de Benedetti F and Martini A (1998) Is systemic juvenile rheumatoid arthritis an interleukin-6 mediated disease? J Rheumatol25: 203–207 CASPubMed Google Scholar
Yokota S (2003) Interleukin-6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis. Curr Opin Rheumatol15: 581–586 ArticleCAS Google Scholar
Fishman D et al. (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest102: 1369–1376 ArticleCAS Google Scholar
Ogilvie EM et al. (2003) The –174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum48: 3202–3206 ArticleCAS Google Scholar
Yokota S et al. (2005) Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum52: 818–825 ArticleCAS Google Scholar
Yokota S et al. (2005) Long-term treatment of systemic-onset juvenile idiopathic arthritis (soJIA) with humanized anti-IL-6 receptor monoclonal antibody, tocilizumab (Actemra) [abstract #1956]. Arthritis Rheum52 (Suppl): S725 Google Scholar
Ram PA and Waxman DJ (1999) SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J Biol Chem274: 35553–35561 ArticleCAS Google Scholar
Woo P et al. (2005) Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther7: R1281–R1288 ArticleCAS Google Scholar
Iwamoto M et al. (2002) Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum46: 3388–3389 ArticleCAS Google Scholar
Yoshizaki K et al. (1989) Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood74: 1360–1367 CASPubMed Google Scholar
Nishimoto N et al. (2000) Improvement in Castleman's disease by humanized anti-IL-6 receptor antibody therapy. Blood95: 56–61 CASPubMed Google Scholar
Nishimoto N et al. (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman's disease. Blood106: 2627–2632 ArticleCAS Google Scholar
Atreya R et al. (2000) Blockade of interleukin-6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med6: 583–588 ArticleCAS Google Scholar
Yamamoto M et al. (2000) IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol164: 4878–4882 ArticleCAS Google Scholar
Ito H et al. (2004) A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology126: 989–996 ArticleCAS Google Scholar
Kishimoto T et al. (1992) Interleukin-6 and its receptor: a paradigm for cytokines. Science258: 593–597 ArticleCAS Google Scholar
Scheller J et al. (2006) Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol63: 321–329 ArticleCAS Google Scholar
Yoshimura A (2005) Negative regulation of cytokine signaling. Clin Rev Allergy Immunol28: 205–220 ArticleCAS Google Scholar